Stefania Conti

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2381953/publications.pdf

Version: 2024-02-01

121	3,090	159585	206112
papers	citations	30 h-index	48 g-index

121	121	121	2272
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Metabolic Plasticity of Candida albicans in Response to Different Environmental Conditions. Journal of Fungi (Basel, Switzerland), 2022, 8, 723.	3.5	8
2	Anti-Infective Antibody-Derived Peptides Active against Endogenous and Exogenous Fungi. Microorganisms, 2021, 9, 143.	3.6	5
3	In Vitro and In Vivo Anti-Candida Activity and Structural Analysis of Killer Peptide (KP)-Derivatives. Journal of Fungi (Basel, Switzerland), 2021, 7, 129.	3.5	7
4	In Silico Predicted Antifungal Peptides: In Vitro and In Vivo Anti-Candida Activity. Journal of Fungi (Basel, Switzerland), 2021, 7, 439.	3.5	5
5	Antimicrobial Peptide L18R Displays a Modulating Action against Inter-Kingdom Biofilms in the Lubbock Chronic Wound Biofilm Model. Microorganisms, 2021, 9, 1779.	3.6	5
6	Wickerhamomyces Yeast Killer Toxinsâ€™ Medical Applications. Toxins, 2021, 13, 655.	3.4	6
7	Therapeutic Effect of an Antibody-Derived Peptide in a Galleria mellonella Model of Systemic Candidiasis. International Journal of Molecular Sciences, 2021, 22, 10904.	4.1	6
8	Activity of Two Antimicrobial Peptides against Enterococcus faecalis in a Model of Biofilm-Mediated Endodontic Infection. Antibiotics, 2021, 10, 1220.	3.7	8
9	A Peptide Found in Human Serum, Derived from the C-Terminus of Albumin, Shows Antifungal Activity In Vitro and In Vivo. Microorganisms, 2020, 8, 1627.	3.6	7
10	Antimicrobial Photodynamic Therapy Protocols on Streptococcus mutans with Different Combinations of Wavelengths and Photosensitizing Dyes. Bioengineering, 2019, 6, 42.	3.5	13
11	Antimicrobial effect on <i>Candida albicans</i> biofilm by application of different wavelengths and dyes and the synthetic killer decapeptide KP. Laser Therapy, 2019, 28, 180-186.	0.3	8
12	Antiviral Activity of Synthetic Peptides Derived from Physiological Proteins. Intervirology, 2018, 61, 166-173.	2.8	21
13	Dissection of the Structural Features of a Fungicidal Antibody-Derived Peptide. International Journal of Molecular Sciences, 2018, 19, 3792.	4.1	6
14	Antimicrobial peptides with antiprotozoal activity: current state and future perspectives. Future Medicinal Chemistry, 2018, 10, 2569-2572.	2.3	19
15	Discovering a new class of antifungal agents that selectively inhibits microbial carbonic anhydrases. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1537-1544.	5.2	15
16	The activity of a mammalian proline-rich peptide against Gram-negative bacteria, including drug-resistant strains, relies on a nonmembranolytic mode of action. Infection and Drug Resistance, 2018, Volume 11, 969-979.	2.7	8
17	Novel Activity of a Synthetic Decapeptide Against Toxoplasma gondii Tachyzoites. Frontiers in Microbiology, 2018, 9, 753.	3.5	23
18	Candidacidal Activity of a Novel Killer Toxin from Wickerhamomyces anomalus against Fluconazole-Susceptible and -Resistant Strains. Toxins, 2018, 10, 68.	3.4	9

#	Article	IF	Citations
19	Effect of different wavelengths and dyes on Candida albicans : In vivo study using Galleria mellonella as an experimental model. Photodiagnosis and Photodynamic Therapy, 2017, 18, 34-38.	2.6	17
20	Fungicidal activity of peptides encoded by immunoglobulin genes. Scientific Reports, 2017, 7, 10896.	3.3	11
21	The synthetic killer peptide KP impairs Candida albicans biofilm in vitro. PLoS ONE, 2017, 12, e0181278.	2.5	25
22	Idiotypic Antifungal Vaccination: Immunoprotection by Antiidiotypic Antibiotic Antibodies. Methods in Molecular Biology, 2017, 1625, 97-112.	0.9	0
23	Natural and synthetic peptides with antifungal activity. Future Medicinal Chemistry, 2016, 8, 1413-1433.	2.3	83
24	A Naturally Occurring Antibody Fragment Neutralizes Infectivity of Diverse Infectious Agents. Scientific Reports, 2016, 6, 35018.	3.3	14
25	Dissecting the Structure-Function Relationship of a Fungicidal Peptide Derived from the Constant Region of Human Immunoglobulins. Antimicrobial Agents and Chemotherapy, 2016, 60, 2435-2442.	3.2	11
26	AFM1 in Milk: Physical, Biological, and Prophylactic Methods to Mitigate Contamination. Toxins, 2015, 7, 4330-4349.	3.4	97
27	Peptides from the inside of the antibodies are active against infectious agents and tumours. Journal of Peptide Science, 2015, 21, 370-378.	1.4	7
28	Photodynamic therapy: a synergy between light and colors. Proceedings of SPIE, 2015, , .	0.8	2
29	Antibodies as a source of anti-infective peptides: an update. Future Microbiology, 2015, 10, 1163-1175.	2.0	8
30	A Wickerhamomyces anomalus Killer Strain in the Malaria Vector Anopheles stephensi. PLoS ONE, 2014, 9, e95988.	2.5	50
31	Antimicrobial activity of poultry bone and meat trimmings hydrolyzates in low-sodium turkey food. Food and Function, 2014, 5, 220-228.	4.6	8
32	In vitro and in vivo activity of a killer peptide against Malassezia pachydermatis causing otitis in dogs. Medical Mycology, 2014, 52, 350-355.	0.7	14
33	Antibodies as an Unlimited Source of Anti-Infective, Anti-Tumour and Immunomodulatory Peptides. Science Progress, 2014, 97, 215-233.	1.9	6
34	Vaccination of Heifers with Anaflatoxin Improves the Reduction of Aflatoxin B1 Carry Over in Milk of Lactating Dairy Cows. PLoS ONE, 2014, 9, e94440.	2.5	13
35	Yeast Killer Toxin-Like Candidacidal Ab6 Antibodies Elicited through the Manipulation of the Idiotypic Cascade. PLoS ONE, 2014, 9, e105727.	2.5	13
36	In vitro bactericidal effect of Nd:YAG laser on Actinomyces israelii. Lasers in Medical Science, 2013, 28, 1131-1135.	2.1	13

#	Article	IF	Citations
37	Structural and functional studies on a proline-rich peptide isolated from swine saliva endowed with antifungal activity towards Cryptococcus neoformans. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 1066-1074.	2.6	14
38	Peptides of the Constant Region of Antibodies Display Fungicidal Activity. PLoS ONE, 2012, 7, e34105.	2.5	41
39	Antibody Constant Region Peptides Can Display Immunomodulatory Activity through Activation of the Dectin-1 Signalling Pathway. PLoS ONE, 2012, 7, e43972.	2.5	17
40	Antibody Peptide Based Antifungal Immunotherapy. Frontiers in Microbiology, 2012, 3, 190.	3.5	26
41	Killer peptide: a novel paradigm of antimicrobial, antiviral and immunomodulatory auto-delivering drugs. Future Medicinal Chemistry, 2011, 3, 1209-1231.	2.3	24
42	From Pichia anomala killer toxin through killer antibodies to killer peptides for a comprehensive anti-infective strategy. Antonie Van Leeuwenhoek, 2011, 99, 35-41.	1.7	43
43	Vaccination of Lactating Dairy Cows for the Prevention of Aflatoxin B1 Carry Over in Milk. PLoS ONE, 2011, 6, e26777.	2.5	21
44	Differential Antitumor Effects of IgG and IgM Monoclonal Antibodies and Their Synthetic Complementarity-Determining Regions Directed to New Targets of B16F10-Nex2 Melanoma Cells. Translational Oncology, 2010, 3, 204-217.	3.7	39
45	Antibodies as Crypts of Antiinfective and Antitumor Peptides. Current Medicinal Chemistry, 2009, 16, 2305-2323.	2.4	36
46	Reversible Self-Assembly: A Key Feature for a New Class of Autodelivering Therapeutic Peptides. Molecular Pharmaceutics, 2009, 6, 1036-1039.	4.6	27
47	Biotyping of Candida albicans and Other Fungi by Yeast Killer Toxins Sensitivity. Methods in Molecular Biology, 2009, 499, 97-115.	0.9	3
48	Antibody Complementarity-Determining Regions (CDRs): A Bridge between Adaptive and Innate Immunity. PLoS ONE, 2009, 4, e8187.	2.5	48
49	Yeast Killer Toxins Technology Transfer. , 2009, , 275-290.		0
50	Structural and functional characterization of the porcine prolineâ€“rich antifungal peptide SPâ€B isolated from salivary gland granules. Journal of Peptide Science, 2008, 14, 251-260.	1.4	22
51	From yeast killer toxins to antibiobodies and beyond. FEMS Microbiology Letters, 2008, 288, 1-8.	1.8	56
52	Therapeutic Activity of an Anti-Idiotypic Antibody-Derived Killer Peptide against Influenza A Virus Experimental Infection. Antimicrobial Agents and Chemotherapy, 2008, 52, 4331-4337.	3.2	28
53	Antibody Complementarity-Determining Regions (CDRs) Can Display Differential Antimicrobial, Antiviral and Antitumor Activities. PLoS ONE, 2008, 3, e2371.	2.5	76
54	Anti-beta-glucan-like immunoprotective candidacidal antiidiotypic antibodies. Frontiers in Bioscience - Landmark, 2008, Volume, 6920.	3.0	16

#	Article	IF	Citations
55	Screening of a Saccharomyces cerevisiae nonessential gene deletion collection for altered susceptibility to a killer peptide. New Microbiologica, 2008, 31, 143-5.	0.1	8
56	Antiidiotype-Derived Killer Peptides As New Potential Tools to Combat HIV-1 and AIDS-Related Opportunistic Pathogens. Anti-Infective Agents in Medicinal Chemistry, 2007, 6, 263-272.	0.6	6
57	In VitroActivity (MIC and MFC) of Voriconazole, Amphotericin B, and Itraconazole Against 192 Filamentous Fungi: The GISIA-2 Study. Journal of Chemotherapy, 2007, 19, 508-513.	1.5	10
58	In vitro candidacidal activity of a synthetic killer decapeptide (KP) against Candida albicans cells adhered to resin acrylic discs. Journal of Oral Pathology and Medicine, 2007, 36, 468-471.	2.7	10
59	A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication. Aids, 2006, 20, 975-980.	2.2	22
60	In vitro antifungal susceptibility to six antifungal agents of 229 Candida isolates from patients with diabetes mellitus. Oral Microbiology and Immunology, 2006, 21, 177-182.	2.8	25
61	Activity of an engineered synthetic killer peptide on Leishmania major and Leishmania infantum promastigotes. Experimental Parasitology, 2006, 113, 186-192.	1.2	30
62	Antiidiotypic DNA vaccination induces serum bactericidal activity and protection against group B meningococci. Journal of Experimental Medicine, 2006, 203, 111-118.	8.5	18
63	Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide. Journal of Leukocyte Biology, 2006, 79, 40-45.	3.3	22
64	In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide. Journal of Antimicrobial Chemotherapy, 2006, 57, 891-898.	3.0	30
65	In vitro activity of a monoclonal killer anti-idiotypic antibody and a synthetic killer peptide against oral isolates of Candida spp. differently susceptible to conventional antifungals. Oral Microbiology and Immunology, 2005, 20, 226-232.	2.8	16
66	Activity of a killer peptide on the growth and ultrastructure of leishmaniae. Journal of Eukaryotic Microbiology, 2005, 52, 38S-43S.	1.7	0
67	Mitochondrial alterations and autofluorescent conversion ofCandida albicans induced by histatins. Microscopy Research and Technique, 2005, 66, 219-228.	2.2	11
68	Protective Antifungal Yeast Killer Toxin-Like Antibodies. Current Molecular Medicine, 2005, 5, 443-452.	1.3	33
69	Production of an Engineered Killer Peptide in Nicotiana benthamiana by Using a Potato virus X Expression System. Applied and Environmental Microbiology, 2005, 71, 6360-6367.	3.1	41
70	Engineered Killer Mimotopes: New Synthetic Peptides for Antimicrobial Therapy. Current Medicinal Chemistry, 2004, 11, 1793-1800.	2.4	25
71	Mycobacterium parmense sp. nov.. International Journal of Systematic and Evolutionary Microbiology, 2004, 54, 1123-1127.	1.7	30
72	Protective Immunization against Group B Meningococci Using Anti-Idiotypic Mimics of the Capsular Polysaccharide. Journal of Immunology, 2004, 172, 2461-2468.	0.8	18

#	Article	IF	Citations
73	Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. Journal of Antimicrobial Chemotherapy, 2004, 54, 956-958.	3.0	41
74	A synthetic peptide as a novel anticryptococcal agent. Cellular Microbiology, 2004, 6, 953-961.	2.1	45
75	Therapeutic potential of yeast killer toxin-like antibodies and mimotopes. FEMS Yeast Research, 2004, 5, 11-18.	2.3	33
76	A Monoclonal Antibody Directed against a Candida albicans Cell Wall Mannoprotein Exerts Three Anti- C. albicans Activities. Infection and Immunity, 2003, 71, 5273-5279.	2.2	150
77	Therapeutic Activity of an Engineered Synthetic Killer Antiidiotypic Antibody Fragment against Experimental Mucosal and Systemic Candidiasis. Infection and Immunity, 2003, 71, 6205-6212.	2.2	104
78	Biotechnological Approaches to the Production of Idiotypic Vaccines and Antiidiotypic Antibiotics. Current Pharmaceutical Biotechnology, 2003, 4, 91-97.	1.6	14
79	First Italian report of onychomycosis caused by Onychocola canadensis. Medical Mycology, 2003, 41, 447-450.	0.7	0
80	Protection of Killer Antiidiotypic Antibodies against Early Invasive Aspergillosis in a Murine Model of Allogeneic T-Cell-Depleted Bone Marrow Transplantation. Infection and Immunity, 2002, 70, 2375-2382.	2.2	67
81	Multicenter Comparative Evaluation of Six Commercial Systems and the National Committee for Clinical Laboratory Standards M27-A Broth Microdilution Method for Fluconazole Susceptibility Testing of Candida Species. Journal of Clinical Microbiology, 2002, 40, 2953-2958.	3.9	58
82	Interplay between Protective and Inhibitory Antibodies Dictates the Outcome of Experimentally Disseminated Candidiasis in Recipients of a Candida albicans Vaccine. Infection and Immunity, 2002, 70, 5462-5470.	2.2	89
83	Engineered Commensal Bacteria as Delivery Systems of Anti-infective Mucosal Protectants. Biotechnology and Genetic Engineering Reviews, 2002, 19, 139-158.	6.2	5
84	New immunotherapeutic strategies to control vaginal candidiasis. Trends in Molecular Medicine, 2002, 8, 121-126.	6.7	33
85	Inhibition by Yeast Killer Toxin-like Antibodies of Oral Streptococci Adhesion to Tooth Surfaces in an Ex Vivo Model. Molecular Medicine, 2002, 8, 313-317.	4.4	29
86	In Vitro Leishmanicidal Activity of a Monoclonal Antibody mimicking a Yeast Killer Toxin. Journal of Eukaryotic Microbiology, 2002, 49, 319-323.	1.7	29
87	Inhibition by yeast killer toxin-like antibodies of oral Streptococci adhesion to tooth surfaces in an ex vivo model. Molecular Medicine, 2002, 8, 313-7.	4.4	8
88	New strategies for treatment of Candida vaginal infections. Revista Iberoamericana De Micologia, 2002, 19, 144-8.	0.9	9
89	Therapy of mucosal candidiasis by expression of an anti-idiotype in human commensal bacteria. Nature Biotechnology, 2000, 18, 1060-1064.	17.5	125
90	Personalized antifungal susceptibility testing. Journal of Antimicrobial Chemotherapy, 1999, 43, 333-338.	3.0	4

#	Article	IF	Citations
91	Factors influencing the expression in vitro of Candida albicans stress mannoproteins reactive with salivary secretory IgA. Mycopathologia, 1998, 141, 1-6.	3.1	2
92	Neonatal mouse immunity against group B streptococcal infection by maternal vaccination with recombinant anti-idiotypes. Nature Medicine, 1998, 4, 705-709.	30.7	64
93	XIX. A transphyletic anti-infectious control strategy based on the killer phenomenon. FEMS Immunology and Medical Microbiology, 1998, 22, 151-161.	2.7	12
94	Killer antibodies in fungal infections. Research in Immunology, 1998, 149, 334-343.	0.9	1
95	Mycobactericidal Activity of Human Natural, Monoclonal, and Recombinant Yeast Killer Toxinâ€like Antibodies. Journal of Infectious Diseases, 1998, 177, 807-811.	4.0	44
96	Effect of Pichia anomala killer toxin on Candida albicans. Medical Mycology, 1998, 36, 199-204.	0.7	0
97	XIX. A transphyletic anti-infectious control strategy based on the killer phenomenon. FEMS Immunology and Medical Microbiology, 1998, 22, 151-161.	2.7	1
98	Inhibitory Effect of Human Natural Yeast Killer Toxin-like Candidacidal Antibodies on Pneumocystis carinii. Molecular Medicine, 1997, 3, 544-552.	4.4	25
99	Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity. Nature Biotechnology, 1997, 15, 155-158.	17.5	136
100	Antibodies, killer toxins and antifungal immunoprotection: a lesson from nature?. Trends in Immunology, 1997, 18, 164-169.	7.5	76
101	Reactivity of Candida albicans Germ Tubes with Salivary Secretory IgA. Journal of Dental Research, 1996, 75, 1979-1985.	5.2	20
102	Killer factor interference in mixed opportunistic yeast cultures. Mycopathologia, 1996, 135, 1-8.	3.1	22
103	Candida albicans stress mannoproteins expression in superficial and systemic candidiasis. Mycopathologia, 1996, 133, 89-94.	3.1	7
104	In Vitro Decrease of Rat-derived Pneumocystis carinii Attachment Induced by Human Natural Yeast Killer Toxin-like Antiidiotypic Candidacidal Antibodies. Journal of Eukaryotic Microbiology, 1996, 43, 27S-27S.	1.7	6
105	Hansenula anomala killer toxin induces secretion and severe acute injury in the rat intestine. Gastroenterology, 1995, 109, 1900-1906.	1.3	40
106	Heat-Shock Mannoproteins as Targets of Secretory IgA in Candida albicans. Journal of Infectious Diseases, 1994, 169, 1401-1405.	4.0	30
107	Killer toxin secretion through the cell wall of the yeastPichia anomala. Mycopathologia, 1994, 126, 173-177.	3.1	14
108	Idiotypic Vaccination: Immunoprotection Mediated by Anti-idiotypic Antibodies with Antibiotic Activity. Scandinavian Journal of Immunology, 1993, 37, 105-110.	2.7	53

#	Article	IF	Citations
109	Inhibitory effect of a yeast killer toxin to the in vitro Pneumocystis carinii attachment. Serodiagnosis and Immunotherapy in Infectious Disease, 1993, 5, 102-106.	0.2	18
110	Ultrastructural immunodetection of a Pichia anomala killer toxin: a preliminary study. Biology of the Cell, 1992, 75, 19-23.	2.0	13
111	Anaerobic yeast killer systems. European Journal of Epidemiology, 1992, 8, 471-476.	5.7	7
112	Genomic studies on killer yeasts belonging to the genusPichia. Antonie Van Leeuwenhoek, 1992, 62, 215-223.	1.7	1
113	Diagnostic potential of IgA coated Candida cells in mucous membrane candidiasis. Mycopathologia, 1991, 116, 105-112.	3.1	7
114	Interfaces of the Yeast Killer Phenomenon. Critical Reviews in Microbiology, 1991, 18, 47-87.	6.1	33
115	Differential toxinogenesis in the genusPichia detected by an anti-yeast killer toxin monoclonal antibody. Antonie Van Leeuwenhoek, 1991, 59, 139-145.	1.7	8
116	Production of yeast killer toxin in experimentally infected animals. Mycopathologia, 1990, 110, 169-175.	3.1	10
117	Detection by immunofluorescent anti-idiotypic antibodies of yeast killer toxin cell wall receptors of Candida albicans. Journal of Immunological Methods, 1990, 132, 205-209.	1.4	39
118	Serological study of yeast killer toxins by monoclonal antibodies. Mycopathologia, 1989, 108, 211-215.	3.1	14
119	Biotyping of pathogenic fungi by the killer system and with monoclonal antibodies. Mycopathologia, 1989, 107, 17-23.	3.1	15
120	Biotyping of bacterial isolates using the yeast killer system. European Journal of Epidemiology, 1989, 5, 303-310.	5.7	33
121	Studies on the epidemiology of Aspergillus fumigatus infections in a university hospital. European Journal of Epidemiology, 1989, 5, 8-14.	5.7	33